HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.

Abstract
Mutations in hemojuvelin (HJV) cause severe juvenile hemochromatosis, characterized by iron loading of the heart, liver, and pancreas. Knockout (KO) mice lacking HJV (Hjv-/-) spontaneously load with dietary iron and, therefore, present a model for hereditary hemochromatosis (HH). In HH, iron chelation may be considered in noncandidates for phlebotomy. We examined the effects of deferasirox, an oral chelator, in Hjv-/- mice. Hepatic, cardiac, splenic, and pancreatic iron were determined by measuring elemental iron and scoring histological sections. Heart and liver iron levels were also determined repeatedly by quantitative R2* magnetic resonance imaging (MRI). The time course of iron loading without intervention was followed from Week 8 of age (study start) to Week 20, when once-daily (5x/week) deferasirox was administered, to Week 28. At 8 weeks, liver iron of KO mice was already markedly elevated versus wild-type mice (P<0.001) and reached a plateau around Week 14. In contrast, Week 8 cardiac and pancreatic iron levels were similar in both KO and wild-type mice and, compared with the liver, showed a delayed but massive iron loading up to Week 20. Contrary to the liver, heart, and pancreas, the KO mice spleen had lower iron content versus wild-type mice. In Hjv-/- mice, liver and heart iron burden was effectively reduced with deferasirox 100 mg/kg (P<0.05). Although deferasirox was less efficacious at this dose in the pancreas, over the observed time period, a clear trend toward reduced organ iron load was noted. There was no noticeable effect of deferasirox upon splenic iron in Hjv-/- mice. Quantitative R2* MRI demonstrated the ability to assess iron concentrations in the liver and myocardial muscle accurately and repetitively. Hepatic (R=0.86; P=3.2*10(-12)) and delayed myocardial (R=0.81; P=2.9*10(-10)) iron accumulation could be followed noninvasively with high agreement to invasive methods.
AuthorsHanspeter Nick, Peter R Allegrini, Lucy Fozard, Ursula Junker, Lisa Rojkjaer, Rishard Salie, Vera Niederkofler, Terrence O'Reilly
JournalExperimental biology and medicine (Maywood, N.J.) (Exp Biol Med (Maywood)) Vol. 234 Issue 5 Pg. 492-503 (May 2009) ISSN: 1535-3702 [Print] England
PMID19234060 (Publication Type: Journal Article)
Chemical References
  • Benzoates
  • GPI-Linked Proteins
  • HJV protein, mouse
  • Hemochromatosis Protein
  • Iron Chelating Agents
  • Membrane Proteins
  • Triazoles
  • Iron
  • Deferasirox
Topics
  • Animals
  • Benzoates (pharmacology, therapeutic use)
  • Deferasirox
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • GPI-Linked Proteins
  • Hemochromatosis (drug therapy, genetics)
  • Hemochromatosis Protein
  • Humans
  • Iron (metabolism)
  • Iron Chelating Agents (pharmacology, therapeutic use)
  • Magnetic Resonance Imaging
  • Membrane Proteins (genetics)
  • Mice
  • Mice, Knockout
  • Organ Specificity
  • Triazoles (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: